CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Understanding who benefits most from opening a Roth IRA helps you decide if this account fits your retirement strategy and tax outlook.
23,663 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
If spacex could make thousands, the IPO narrative could reshape your retirement plan—but only with careful analysis. ...
Joby Aviation stock has been on a wild ride as headlines swirl around the company and the eVTOL market. This article ...
A luxury of near-new mileage becomes a liability if a dealer claims a major repair. This article breaks down what hap...
Tuesday brought a notable standout in the banking space as JPMorgan Chase topped market momentum. This piece breaks d...
SpaceX has entered another slide in its public debut era. This article breaks down what a second day of losses could ...
Celsius is already generating strong margins, and that has investors rethinking how high profits could go. This artic...
When the AI rally paused, investors turned to dependable dividend names. Johnson Johnson, Altria, and Verizon led gai...
Cerebras' first earnings report brings a clear message for AI stock shoppers: growth alone isn't enough. Here's how t...
SpaceX's Starlink program could redefine internet access and investor value. This year’s launch pace hinges on regula...
A bipartisan push in Congress seeks a federal registry for trusted AI agents and a fiduciary standard for robo-adviso...
Two sector income ETFs are delivering yields well above the S&P 500 as investors price in a possible recession. The g...